FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2527458261> ?p ?o ?g. }

• W2527458261 endingPage "5750" @default.
• W2527458261 startingPage "5737" @default.
• W2527458261 abstract "The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer Hongchao Jiang,1,2 Ceshi Chen,3 Qiangming Sun,4 Jing Wu,3 Lijuan Qiu,4 Change Gao,5 Weiqing Liu,5 Jun Yang,5 Nie Jun,2 Jian Dong2 1Department of Oncology, The Affiliated Children’s Hospital of Kunming Medical University, 2Department of Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Provincial Tumor Hospital, 3Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, 4Molecular Epidemiology Joint Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, 5Department of Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China Background: Semaphorin 4D (Sema4D) is highly expressed in certain types of tumors and functions in the regulation of tumor angiogenesis and growth. However, it is still not clear regarding the roles of Sema4D in breast cancer. This study was designed to explore the effects of Sema4D on proliferation, cell cycle progression, apoptosis, invasion, migration, tumor growth, and angiogenesis in breast cancer.Materials and methods: The expression level of Sema4D was investigated in MCF10A, 184A1, HCC1937, MDA-MB-468, MDA-MB-231, Hs578T, BT474, MCF-7, and T47D breast cancer cell lines by Western blotting analysis. Sema4D downregulation or overexpression was established by infection with lentiviruses-encoding Sema4D short hairpin RNA (shRNA) or Sema4D. To evaluate the effects of Sema4D on cell proliferation, cell cycle progression, apoptosis, invasion, and migration of MDA-MB-231 and MDA-MB-468 cells, methods including MTT assay, flow cytometry, wound healing assay, and transwell experiments were applied. BALB/c nude mice were injected with MDA-MB-231 cells, which were respectively infected with lentiviruses-encoding Sema4D, Sema4D shRNA, and GFP, followed by tumor angiogenesis assay.Results: Sema4D was expressed at higher levels in breast cancer cell lines compared with the normal human breast epithelial cell lines, especially in MDA-MB-231 and MDA-MB-468 cells. Cell proliferation ability was remarkably inhibited in Sema4D downregulated condition, whereas the proportions of cells in the G0/G1 phase and apoptosis increased in MDA-MB-231 and MDA-MB-468 cells. In addition, the invasion and migration abilities of these cells were obviously reduced. Xenograft growth as well as angiogenesis was inhibited when infected with lentiviruses-encoding Sema4D shRNA in vivo.Conclusion: Downregulation of Sema4D had notable influence on cell proliferation ability, invasion, migration, and apoptosis of both MDA-MB-231 and MDA-MB-468 cells. Furthermore, infection with lentiviruses-encoding Sema4D shRNA obviously inhibited tumor growth and angiogenesis in BALB/c nude mice. Our results showed that Sema4D may represent a novel therapeutic target for human breast cancer. Keywords: semaphorin 4D, breast cancer, apoptosis, angiogenesis, proliferation" @default.
• W2527458261 created "2016-10-07" @default.
• W2527458261 creator A5002845405 @default.
• W2527458261 creator A5018028379 @default.
• W2527458261 creator A5018342513 @default.
• W2527458261 creator A5047917101 @default.
• W2527458261 creator A5050140916 @default.
• W2527458261 creator A5058427851 @default.
• W2527458261 creator A5071537189 @default.
• W2527458261 creator A5071624993 @default.
• W2527458261 creator A5071896176 @default.
• W2527458261 creator A5081946580 @default.
• W2527458261 date "2016-09-01" @default.
• W2527458261 modified "2023-10-06" @default.
• W2527458261 title "The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer" @default.
• W2527458261 cites W137567947 @default.
• W2527458261 cites W147652200 @default.
• W2527458261 cites W1488893964 @default.
• W2527458261 cites W1967233586 @default.
• W2527458261 cites W1975540542 @default.
• W2527458261 cites W1977276208 @default.
• W2527458261 cites W1981449360 @default.
• W2527458261 cites W1983256377 @default.
• W2527458261 cites W1985723830 @default.
• W2527458261 cites W1988011969 @default.
• W2527458261 cites W1988031547 @default.
• W2527458261 cites W1991899045 @default.
• W2527458261 cites W1995616389 @default.
• W2527458261 cites W1997108574 @default.
• W2527458261 cites W2009761723 @default.
• W2527458261 cites W2014308349 @default.
• W2527458261 cites W2019241142 @default.
• W2527458261 cites W2029676294 @default.
• W2527458261 cites W2035278484 @default.
• W2527458261 cites W2048607934 @default.
• W2527458261 cites W2055503691 @default.
• W2527458261 cites W2057515046 @default.
• W2527458261 cites W2075484250 @default.
• W2527458261 cites W2079563393 @default.
• W2527458261 cites W2084243189 @default.
• W2527458261 cites W2090305122 @default.
• W2527458261 cites W2091880217 @default.
• W2527458261 cites W2096644496 @default.
• W2527458261 cites W2099063881 @default.
• W2527458261 cites W2141359150 @default.
• W2527458261 cites W2148357240 @default.
• W2527458261 cites W2152263766 @default.
• W2527458261 cites W2158556013 @default.
• W2527458261 cites W2160235599 @default.
• W2527458261 cites W2179937039 @default.
• W2527458261 cites W2188735123 @default.
• W2527458261 cites W2295822595 @default.
• W2527458261 cites W2408222419 @default.
• W2527458261 cites W2409212786 @default.
• W2527458261 doi "https://doi.org/10.2147/ott.s114708" @default.
• W2527458261 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5045906" @default.
• W2527458261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27729799" @default.
• W2527458261 hasPublicationYear "2016" @default.
• W2527458261 type Work @default.
• W2527458261 sameAs 2527458261 @default.
• W2527458261 citedByCount "24" @default.
• W2527458261 countsByYear W25274582612017 @default.
• W2527458261 countsByYear W25274582612018 @default.
• W2527458261 countsByYear W25274582612019 @default.
• W2527458261 countsByYear W25274582612020 @default.
• W2527458261 countsByYear W25274582612021 @default.
• W2527458261 countsByYear W25274582612022 @default.
• W2527458261 countsByYear W25274582612023 @default.
• W2527458261 crossrefType "journal-article" @default.
• W2527458261 hasAuthorship W2527458261A5002845405 @default.
• W2527458261 hasAuthorship W2527458261A5018028379 @default.
• W2527458261 hasAuthorship W2527458261A5018342513 @default.
• W2527458261 hasAuthorship W2527458261A5047917101 @default.
• W2527458261 hasAuthorship W2527458261A5050140916 @default.
• W2527458261 hasAuthorship W2527458261A5058427851 @default.
• W2527458261 hasAuthorship W2527458261A5071537189 @default.
• W2527458261 hasAuthorship W2527458261A5071624993 @default.
• W2527458261 hasAuthorship W2527458261A5071896176 @default.
• W2527458261 hasAuthorship W2527458261A5081946580 @default.
• W2527458261 hasBestOaLocation W25274582611 @default.
• W2527458261 hasConcept C121608353 @default.
• W2527458261 hasConcept C126322002 @default.
• W2527458261 hasConcept C132538176 @default.
• W2527458261 hasConcept C143998085 @default.
• W2527458261 hasConcept C170493617 @default.
• W2527458261 hasConcept C173396325 @default.
• W2527458261 hasConcept C190232843 @default.
• W2527458261 hasConcept C190283241 @default.
• W2527458261 hasConcept C2780394083 @default.
• W2527458261 hasConcept C502942594 @default.
• W2527458261 hasConcept C530470458 @default.
• W2527458261 hasConcept C54355233 @default.
• W2527458261 hasConcept C55493867 @default.
• W2527458261 hasConcept C62112901 @default.
• W2527458261 hasConcept C71924100 @default.
• W2527458261 hasConcept C86803240 @default.
• W2527458261 hasConceptScore W2527458261C121608353 @default.
• W2527458261 hasConceptScore W2527458261C126322002 @default.

• next